Pre-eclampsia, a pregnancy-specific multi-organ syndrome characterized by widespread endothelial damage, is a new risk factor for cardiovascular disease. No therapies exist to prevent or treat this condition, even to achieve a modest improvement in pregnancy length or birth weight. Co-administration of soluble VEGFR-1 [VEGF (vascular endothelial growth factor) receptor-1; more commonly known as sFlt-1 (soluble Fms-like tyrosine kinase-1)] and sEng (soluble endoglin) to pregnant rats elicits severe pre-eclampsia-like symptoms. These two anti-angiogenic factors are increased dramatically prior to the clinical onset of pre-eclampsia and are quite possibly the ‘final common pathway’ responsible for the accompanying signs of hypertension and proteinuria as they can be reversed by VEGF administration in animal models. HO-1 (haem oxygenase-1), an anti-inflammatory enzyme, and its metabolite, CO (carbon monoxide), exert protective effects in several organs against oxidative stimuli. In a landmark publication, we showed that the HO-1 pathway inhibits sFlt-1 and sEng in cultured cells and human placental tissue explants. Both CO and NO (nitric oxide) promote vascular homoeostasis and vasodilatation, and activation of VEGFR-1 or VEGFR-2 induced eNOS (endothelial nitric oxide synthase) phosphorylation, NO release and HO-1 expression. Our studies established the HO-1/CO pathway as a negative regulator of cytokine-induced sFlt-1 and sEng release and eNOS as a positive regulator of VEGF-mediated vascular morphogenesis. These findings provide compelling evidence for a protective role of HO-1 in pregnancy and identify it as a target for the treatment of pre-eclampsia. Any agent that is known to up-regulate HO-1, such as statins, may have potential as a therapy. Any intervention achieving even a modest prolongation of pregnancy or amelioration of the condition could have a significant beneficial health impact worldwide.
Skip Nav Destination
Article navigation
December 2009
- Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 19 2009
Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?
Asif Ahmed;
Asif Ahmed
1
*Department of Reproductive and Vascular Biology, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
†Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, U.K.
1To whom correspondence should be addressed (email a.s.ahmed@bham.ac.uk).
Search for other works by this author on:
Melissa J. Cudmore
Melissa J. Cudmore
*Department of Reproductive and Vascular Biology, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
†Birmingham Women's Hospital, Edgbaston, Birmingham B15 2TG, U.K.
Search for other works by this author on:
Biochem Soc Trans (2009) 37 (6): 1237–1242.
Article history
Received:
July 07 2009
Accepted Manuscript online:
August 28 2009
Citation
Asif Ahmed, Melissa J. Cudmore; Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochem Soc Trans 1 December 2009; 37 (6): 1237–1242. doi: https://doi.org/10.1042/BST0371237
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.